ArticleSarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG2025
Bioinformatics analysis identifies candidate biomarkers associated with sarcoidosis.
Article in Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Subclinical cardiac involvement: A subtle foe in the setting of systemic sarcoidosis.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimSarcoidosis is a complex inflammatory disorder characterized by the formation of non-caseating granulomas, which can affect multiple systems, with a predominant impact on the lungs and thoracic lymph nodes. The aim of the study is to identify potential biomarkers and explore the infiltration of immune cells associated with sarcoidosis. Methods: The datasets of GSE19314, GSE83456, and GSE37912 were obtained from the Gene Expression Omnibus (GEO) database. Differentially expressed genes (DEGs) were screened by comparing sarcoidosis samples to healthy controls in GSE19314 and GSE83456. Functional enrichment analyses and protein-protein interactions (PPIs) network construction were performed to elucidate the functional roles of the DEGs. Hub genes were identified through PPI network analysis. The GSE37912 dataset was used as a validation set. Immune cell infiltration in sarcoidosis patients was investigated. Furthermore, the trehalose 6,6'-dimycolate-granuloma (TDM)-induced granuloma experimental model was employed to resemble human sarcoid granulomas, and the expression of hub genes in lung tissues was detected by qRT-PCR.
resultsA total of 71 common DEGs, including 53 upregulated DEGs and 18 downregulated DEGs, were identified between sarcoidosis patients and controls. The signal transducer and activator of transcription 1 (STAT1), C-X-C motif chemokine ligand 10 (CXCL10) and basic leucine zipper ATF-like transcription factor 2 (BATF2) were considered as hub genes, showing promising diagnostic potential for sarcoidosis. Immune infiltration analysis indicated that compared with the controls, sarcoidosis samples exhibited increased infiltration of activated NK cells, monocytes, macrophage, activated dendritic cells and resting mast cells. In the TDM-induced lung granuloma model, STAT1, CXCL10 and BATF2 expression was upregulated in sarcoidosis lung tissue.
conclusionsBioinformatics analysis indicated that STAT1, CXCL10 and BATF2 may as candidate biomarkers associated with sarcoidosis.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.